Roniciclib

Research use only, not for human use.

A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.

A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM; inhibits 16 additional kinase in a panel of 214 non-CDK Ser/Thr and Tyr kinases; simultaneously inhibits cell-cycle progression and RNA polymerase II-mediated gene transcription, shows broad and uniform inhibitory activity on cell proliferation with IC50 of 8-33 nM, potently inhibits growth of various human tumor xenografts.Lung Cancer Phase 2 Discontinued

BAY 10-00394;BAY1000394

Angiogenesis

CDK

CDK

Cancer

Lung Cancer

1223498-69-8

430.44

C18H21F3N4O3S

>98% (HPLC)

——

C[C@@H](O)[C@H](OC1=NC(NC2=CC=C(S(=N)(C3CC3)=O)C=C2)=NC=C1C(F)(F)F)C

(R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide

(-20℃)

With Ice Pack

≥ 2 years